Isolate highly purified human CD138+ (syndecan-1) cells from fresh bone marrow or whole blood samples by immunomagnetic positive selection, with the EasySep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Kit II. Widely used in published research for more than 20 years, EasySep™ combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.
In this EasySep™ positive selection procedure, desired cells are labeled with antibody complexes recognizing CD138+ (syndecan-1) and dextran-coated magnetic particles. The cocktail in this kit also contains an antibody to human Fc receptor to prevent non-specific binding. Labeled cells are separated using an EasySep™ magnet and by simply pouring or pipetting off the unwanted cells. The cells of interest remain in the tube. Following magnetic cell isolation, the desired CD138+ cells are ready for downstream applications such as fluorescence in situ hybridization (FISH), flow cytometry, culture, or DNA/RNA extraction. The CD138 antigen is expressed on normal and malignant plasma cells (but not mature B cells).
This product replaces the EasySep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Kit (Catalog #18387) for even faster cell isolations.
Take our free On-Demand CD138+ Cell Isolation Course to learn how to process bone marrow samples and isolate CD138+ plasma cells to increase sensitivity in FISH testing for multiple myeloma. You can also browse our Frequently Asked Questions (FAQs) about isolating CD138+ plasma cells to improve FISH sensitivity.
Learn more about how immunomagnetic EasySep™ technology works or how to fully automate immunomagnetic cell isolation with RoboSep™. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.
Starting with fresh whole blood spiked with a multiple myeloma cell line, U266, the CD138+ cell content of the selected fraction typically ranges from 83.7 - 98.3%. In the above example, the purities of the start and final isolated fractions are 9.1% and 90.4%, respectively. NOTE: For samples with CD138+ starting frequency < 10 - 15%, the CD138+ purity of the isolated fraction may be variable. NOTE: Red blood cells were removed from the start sample by lysis prior to flow cytometry.
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. R. Sakemura et al. Blood 2022 jun
Abstract
Pivotal clinical trials of B-cell maturation antigen-targeted chimeric antigen receptor T (CART)-cell therapy in patients with relapsed/refractory multiple myeloma (MM) resulted in remarkable initial responses, which led to a recent US Food and Drug Administration approval. Despite the success of this therapy, durable remissions continue to be low, and the predominant mechanism of resistance is loss of CART cells and inhibition by the tumor microenvironment (TME). MM is characterized by an immunosuppressive TME with an abundance of cancer-associated fibroblasts (CAFs). Using MM models, we studied the impact of CAFs on CART-cell efficacy and developed strategies to overcome CART-cell inhibition. We showed that CAFs inhibit CART-cell antitumor activity and promote MM progression. CAFs express molecules such as fibroblast activation protein and signaling lymphocyte activation molecule family-7, which are attractive immunotherapy targets. To overcome CAF-induced CART-cell inhibition, CART cells were generated targeting both MM cells and CAFs. This dual-targeting CART-cell strategy significantly improved the effector functions of CART cells. We show for the first time that dual targeting of both malignant plasma cells and the CAFs within the TME is a novel strategy to overcome resistance to CART-cell therapy in MM.
Thank you for your interest in IntestiCult™ Organoid Growth Medium (Human). Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they
can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our
privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
